^
Association details:
| Biomarker: | HER-2 amplification + AXL expression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Published date:
05/20/2022
Excerpt:
AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis.....Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression.
Secondary therapy:
AXL inhibitor
DOI:
10.1126/sciadv.abk2746
